SEP 07, 2020 8:00 AM PDT

CRISPR Pumps the Brakes on the Immune System to Support Gene Therapies

WRITTEN BY: Tara Fernandez

The ability to edit the human genome using CRISPR has been heralded as a revolution in medicine. However, one of the biggest challenges facing gene therapies is getting this molecule gene-editing machinery into cells. Among the most common delivery approaches is the use of viruses such as the adeno-associated virus (AAV), which shuttle CRISPR into the nuclei of cells where these molecular scissors can then make edits to the defective gene. 

The immune system shields us from invading pathogens and CRISPR-bearing AAVs are no exception. Consequently, patients can launch strong immune responses against gene therapies, rendering them useless.

In designing a means of side-stepping these immune reactions, scientists at the University of Pittsburgh are once again turning to CRISPR. A newly developed system temporarily hits pause on genes associated with the production of antibodies against AAV. This suspension of the immune system provides AAV with a safe passage into cells where they can drop off their CRISPR cargoes without immune intervention.

“Many clinical trials fail because of the immune response against AAV gene therapy,” said Samira Kiani, senior author of the study which was published in Nature Cell Biology. “And then you can’t readminister the shot because people have developed immunity.”

The scientists validated their system of controlling the immune system with CRISPR in an experimental mouse model. They first administered AAVs bearing CRISPR sequences that pumped the brakes on the immune system. The second infusion of AAV contained CRISPR targeting another gene to simulate gene therapy. Promisingly, the mice did not mount an immune response against the second shot of AAV, with the therapy working much more efficiently than in control animals.

Kiani has gone on to launch SafeGen Therapeutics, a start-up aimed at bringing this technology to the clinic.

Sources: Nature Cell Biology, Technology Networks.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 22, 2021
Immunology
"Stunning" Anti-Inflammatory Effects of a Fermented Food Diet
JUL 22, 2021
"Stunning" Anti-Inflammatory Effects of a Fermented Food Diet
Researchers at Stanford University have found that consuming fermented foods such as yogurt, sauerkraut, and kombucha te ...
JUL 27, 2021
Immunology
Rethinking Immune Responses Involved in Skin Hypersensitivity
JUL 27, 2021
Rethinking Immune Responses Involved in Skin Hypersensitivity
A study by immunologists at the University of Copenhagen has revealed a never-before-seen immune pathway invol ...
AUG 18, 2021
Cannabis Sciences
Cannabis Use Disorder Linked to COVID Hospitalization
AUG 18, 2021
Cannabis Use Disorder Linked to COVID Hospitalization
People with a genetic predisposition to cannabis use disorder (CUD) are more likely to require hospitalization after con ...
AUG 31, 2021
Health & Medicine
People Who Have Had SARS-CoV-2 Infection Have Longer-Lasting Immunity Than Those Who Were Vaccinated Only
AUG 31, 2021
People Who Have Had SARS-CoV-2 Infection Have Longer-Lasting Immunity Than Those Who Were Vaccinated Only
Consider yourself among the luckiest if you made a full recovery from infection with SARS-CoV-2, especially if you were ...
OCT 07, 2021
Cancer
Dual Threat: CAR T Cells Modified to Target Two Neuroblastoma Antigens
OCT 07, 2021
Dual Threat: CAR T Cells Modified to Target Two Neuroblastoma Antigens
Neuroblastoma is a cancer of immature nerve cells found in various areas, including the adrenal glands, neck, chest ...
OCT 18, 2021
Cancer
The History of Immunotherapy: Toxins, Targets & T Cells
OCT 18, 2021
The History of Immunotherapy: Toxins, Targets & T Cells
Cancer immunotherapy, a treatment that directly enhances a patient’s immune system, is typically perceived as a mo ...
Loading Comments...